Back to Trials
NCT05723107PHASE1Recruiting

EUS RFA for Treatment of Pancreatic Ductal Adenocarcinoma (PDAC)

NYU Langone Health

Start Date

3/31/2023

Completion Date

3/1/2028

Summary

This is a single arm study in the treatment of pancreatic ductal adenocarcinoma (PDAC). The investigators propose to test the tolerability of chemotherapy plus endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) using the RF Electrode in patients receiving palliative second or third line therapy for unresectable non-metastatic pancreatic cancer.

Eligibility Criteria

Age Range: 18 years to No maximum

Inclusion Criteria: * Diagnosed and histologically confirmed PDAC by biopsy * Axial CT scan or MRI consistent with PDAC with at least 1 cm in greatest diameter * ECOG performance status 0-2 * Patients with locally advanced PDAC, who have not responded or progressed on first line chemotherapy, are deemed not resectable based on multidisciplinary review, and show no evidence of distant metastasis * Lesions between 1 - 4cm in size Exclusion Criteria: * Patients that show evidence of distant metastasis * Endoscopically non-accessible mass * Pregnant patients * Inability to provide informed consent * Lesions \<1cm, or \>4cm in greatest diameter

Interventions

DRUG

Chemotherapy

DEVICE

Endoscopic Ultrasound-Guided Radiofrequency Ablation (EUS-RFA)

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Pancreatic Cancer

Locations

Tisch Hospital

New York, New York 10016

United States